{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.84","value":"76.1"},{"groupId":"OG001","spread":"12.95","value":"77.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"327"}],"units":"Participants"}],"title":"Baseline (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.81","value":"0.3"},{"groupId":"OG001","spread":"9.98","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"},{"groupId":"OG001","value":"286"}],"units":"Participants"}],"title":"Change at Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.10","value":"-0.2"},{"groupId":"OG001","spread":"10.20","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"title":"Change at Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.84","value":"-0.5"},{"groupId":"OG001","spread":"11.26","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"title":"Change at Cycle 4, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.32","value":"0.4"},{"groupId":"OG001","spread":"11.45","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Change at Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.54","value":"-0.8"},{"groupId":"OG001","spread":"10.52","value":"-2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Change at Cycle 6, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.89","value":"-0.6"},{"groupId":"OG001","spread":"11.48","value":"-2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Change at Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.25","value":"2.5"},{"groupId":"OG001","spread":"12.45","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"235"}],"units":"Participants"}],"title":"Change at End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"description":"Vital signs included blood pressure and pulse rate. Changes from baseline in sitting pulse rate were summarized.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion of 10 milligrams per kilograms (mg/kg) of Avelumab along with BSC, on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered as per the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"OG000","title":"Avelumab + Best Supportive Care (BSC)"},{"description":"As prescribed by the treating physician, participants received BSC which included treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"OG001","title":"Best Supportive Care"}],"paramType":"MEAN","populationDescription":"Safety set analyzed. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table; however, may not have evaluable data for every row. Here, 'Number analyzed' = participants evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline (Day [D] 1 of Cycle [C] 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7 , EOT visit (for a maximum duration of 41 months) (each cycle=28 days)","title":"Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit","type":"SECONDARY","unitOfMeasure":"beats per minute"}